2874 results about "Magnesium salt" patented technology

The present invention relates to a method and transdermal pharmaceutical composition for preventing magnesium deficiency or imbalances associated with magnesium deficiency including diabetes, hypertension, high cholesterol, cardiac arrhythmias, acute myocardial infarction, arteriosclerosis, atherosclerosis, preeclampsia, dysautonomia, mitral valve prolapse, asthma, constipation, irritable bowel syndrome, migraines, muscle spasms and cramping, premenstrual syndrome, osteoporosis, kidney stones, chronic fatigue syndrome, and fibromyalgia. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of magnesium and a pharmaceutically acceptable carrier. A therapeutically effective amount of a pharmaceutically acceptable salt of zinc a vitamin such as B-complex vitamin, a carotenoid, a mineral, or a combination thereof may also be included in the transdermal pharmaceutical composition. A therapeutically effective amount of progesterone may also be included in the transdermal pharmaceutical composition. The transdermal pharmaceutical composition may be topically administered to prevent magnesium deficiency or imbalances caused by magnesium deficiency.

An oral solid compress composition comprising a magnesium salt is provided. The composition provides a rapid dissolution of the magnesium salt, wherein not less than 75% of the magnesium salt dissolves within 45 minutes after placement in hydrochloric acid (0.1 N, 900 mL) as per USP Method <711>. In a particular embodiment, the magnesium salt is an inorganic salt such as MgO, Mg(OH)₂, MgCl₂, and others. The composition can be prepared by dry granulation, direct compression or another suitable process. The composition provides a substantially stable dissolution profile for the magnesium salt so that the dissolution profile changes only minimally even after an extended period of storage under pharmaceutically acceptable conditions when packaged in a sealed container-enclosure system. The solid composition may also exclude a cellulose-based composition. The compressed composition can be prepared and stored under anhydrous conditions.

The invention relates to compositions for use in purgatives, to purgatives comprising such compositions, and to methods for inducing purgation of the colon. The composition may comprise at least one water-soluble sodium salt; at least one water-soluble minimally degradable sugar in an amount, by weight, of from about 1 to about 3 times the weight of sodium ions in said composition; at least one water-soluble potassium salt in an amount, by weight, of from about 0.05 to about 1 time the weight of said sodium salt in said composition; and at least one water-soluble magnesium salt, wherein the weight of magnesium ions in said composition is from 0.1 to about 10 times the weight of sodium ions in said composition.

The present invention relates to the preparation process of high purity aragonite type calcium carbonate whisker. The present invention prepares aragonite type calcium carbonate whisker with lime or slaked lime as main material and magnesium salt as crystal salt controlling agent and through a CO2 carbonating process. The process features the repeated use of the magnesium salt solution and the homogeneous replenishment of lime slurry during carbonating reaction. The process has low production cost, less environmental pollution and high calcium carbonate whisker yield, and the prepared calcium carbonate whisker has high purity and high length/diameter ratio. The process is suitable for industrial production of calcium carbonate whisker.

A pharmaceutical composition containing a magnesium salt and an osmotic hypertonic agent, like a mannitol, is disclosed. Also disclosed are methods of treating individuals who have suffered a neurological insult, such as traumatic brain injury.

The invention relates to an oxygen delignification processing method of grass unbleached chemical pulp. The oxygen delignification of the pulp is processed after cooking and before bleaching. Its rigidity before the oxygen delignification is potassium permanganate value 16-28 (equals to karber value 26-50). After pumping into the oxygen delignification reaction tower and inflating sodium hydroxide, magnesium salt and oxygen, the chemical pulp happen the oxygen delignification in the reaction tower. The chemical pulp with rigidity of potassium permanganate value 10-14 (equals to karber value 14-18) is achieved after the oxygen delignification. The invention can remove the lignin in the pulp effectively and the removal rate is 86-98%. It reduces the degradation of the cellulose to simplify the bleaching process and cut down the dosage of the chemicals. The bleached pulp has good rigidity and drainability. The breaking length of the pulp can reach 4500-8000m and its fold-resistant times can reach 20-70.

A magnesium battery, having an anode containing magnesium; a cathode stable to a voltage of at least 2.6 V relative to a magnesium reference; and an electrolyte containing an electrochemically active magnesium salt obtained by reaction of a Grignard reagent or Hauser base with a boron compound of formula BR₃ is provided. The electrolyte is stable to 2.6 E.V. vs. Mg in the presence of stainless steel.

Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”), a dissolution/stabilization agent such as citric acid, a magnesium salt, and, optionally, additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations by mixing them with a vial containing dry powder excipients that accelerate their absorption. Devices for mixing excipient and insulin together at the time of administration, while minimizing residence time of the mixture, are also described.

The invention discloses a heating-free non-alkali liquid accelerator for jetting concrete and a preparation method of the heating-free non-alkali liquid accelerator. The liquid accelerator is prepared from the following components in percentage by mass: 30%-55% of aluminum sulfate, 3%-10% of aluminium hydroxide, 10%-18% of hydrofluoric acid, 8%-25% of magnesium salt, 1%-8% of alkylol amine, 0.5%-4% of a stabilizer, and 10%-33% of water. The preparation method is characterized by comprising the following processing steps: putting aluminium hydroxide into a reaction kettle; adding water to the reaction kettle, and stirring aluminium hydroxide into paste; slowly adding hydrofluoric acid, and when the temperature reaches 50-55 DEG C, adding aluminum sulfate to stir in batches; after hydrofluoric acid is completely added, adding residual aluminum sulfate and supplementing residual water, so as to obtain reaction liquid; adding the magnesium salt to the reaction liquid, and then adding the alkylol amine and the stabilizer, so that the solution becomes evenly mixed liquid. The accelerator disclosed by the invention has strong adaptability with cement, low energy consumption and good performance, and does not need to be heated in the use procedure.

The invention relates to the dihydrate of the magnesium salt of pantoprazole.

Fire fighting foam concentrates, expanded foam compositions, and processes of forming a foam composition using a composition comprising: a carbonised saccharide composition, a cross-linking agent or inorganic salt, a surfactant, and water. Augmented with urea or derivatives thereof and/or magnesium salts the disclosed compositions provide improved foaming compositions which also exhibit good biodegradability and environmental compatibility and have particular utility in addressing polar solvent fires such as those of methanol or acetone.

A method of treating headache is provided using a water soluble magnesium salt. Specifically, a method of treating a headache is provided for an individual having a serum ionized magnesium concentration of 0.44 mmoles/L to 0.53 mmoles/L and having at least one headache symptom by administering an amount of a water soluble magnesium salt sufficaent to inhibit at least one headache symptom in the individual within 24 hours and to raise the serum ionized magnesium concentration in the individual to within a normal ionized magnesium concentration range of 0.54 mmoles/L to 0.67 mmoles/L. Headache symptoms which may be inhibited include: pain, aura, photophobia, nausea, unilateral pain and phonophobia.

PCT No. PCT/SE97/00674 Sec. 371 Date Jul. 10, 1997 Sec. 102(e) Date Jul. 10, 1997 PCT Filed Apr. 22, 1997 PCT Pub. No. WO97/41114 PCT Pub. Date Nov. 6, 1997A novel process for the preparation of a magnesium salt of Formula I of a substituted sulfinyl heterocyclic compound containing an imidazole moiety. The process is carried out by mixing the substituted heterocycle of formula I with a weak and a magnesium source. The base and the magnesium source are selected to result in residues which are easy to remove during the reaction. The invention also relates to the use of the produced compounds in medicine.

A stable sodium-free aqueous seasoning solution of agreeable salty taste, adapted as a substitute for common salt in cooked and uncooked foodstuffs, containing purified water, an organic acid, a potassium salt, a calcium salt, and a magnesium salt. The mineral solution provides a dietary supplementation of magnesium, calcium, and potassium—indispensable minerals of a diet—to which colorants, natural essences and artificial essences (singly or in combination), and low concentrations of sodium chloride may be added.

An enhanced activity aqueous disinfecting solution having a pH of from about 0.5 to about 6 and consisting essentially of (i) hydrogen peroxide in a concentration of from about 0.05 to about 8 w/w % of the solution; (ii) at least one anionic surfactant selected from the group consisting of C8 to C16 alkyl aryl sulfonic acids and alkali metal, ammonium, ethanolamine, calcium and magnesium salts thereof, sulfonated C12 to C22 carboxylic acids and alkali metal, ammonium, calcium and magnesium salts thereof, C6 to C22 alkyl diphenyl oxide sulfonic acids and alkali metal, ammonium, ethanolamine, calcium and magnesium salts thereof, naphthalene sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof, C8 to C22 alkyl sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof, alkali metal, ammonium, calcium and magnesium C8 to C18 alkyl sulfates, alkyl or alkenyl esters or diesters of sulfosuccinic acid in which the alkyl or alkenyl groups independently contain from six to eighteen carbon atoms and alkali metal, ammonium, calcium and magnesium salts thereof, and mixtures thereof, in a concentration range of from about 0.02 to about 8 w/w % of the solution. Optionally, the solution may contain (iii) at least one additional ingredient chosen from a monocarboxylic acid, a polycarboxylic acid, and mixtures thereof, in a concentration of from about 0.05 to about 4 w/w % of the solution; and (iv) at least one further additional ingredient chosen from benzyl alcohol, an alcohol comprising one to six carbon atoms, and mixtures thereof, in a concentration of from about 0.1 to about 10 w/w % of the solution.

The novel optically pure compounds Na⁺, Mg²⁺, Li⁺, K⁺, Ca²⁺ and N⁺(R)₄ salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.

The invention provides a method for separating and extracting tungsten-molybdenum from mixed solution of tungstate-molybdate. The method is characterized by: adding aluminum salt or magnesium salt for purification and impurity removal, adding calcium carbonate to precipitate tungsten selectively to obtain artificial scheelite, making the liquid obtained after tungsten precipitation subjected to absorption by ion exchange resin or extraction by a solvent extraction agent to obtain ammonium molybdate, adding acid into the artificial scheelite for decomposition to obtain artificial tungstic acid, and performing ammonia dissolution and crystallization of the artificial tungstic acid to obtain ammonium tungstate. Therefore, effective separation and recovery of tungsten and molybdenum are realized; and in addition, the method has the advantages of short flow, high process adaptability, low consumption of reagents, low processing cost, high recovery rate of metal, good operating environment, and the like.

The present invention relates to compositions and methods employing a water soluble magnesium compound. In certain embodiments, the composition includes water and water soluble magnesium compound, but lacks other materials commonly used in cleaning compositions. The methods and compositions can provide magnesium ion at predefined ratios to calcium ion in water, such as magnesium ion in a molar amount equal to or in excess over a molar amount of calcium ion. A water soluble magnesium salt including an anion of a water soluble calcium salt is more effective than a magnesium salt with an anion of a water insoluble calcium salt. These compositions can be used for reducing lime scale or precipitate formation from hard water, removing soap scum, or the like.

The invention discloses a catalyst and a method used for preparing 1,3-butadiene by oxidative dehydrogenation of n-butene. The catalyst is a cobalt and magnesium modified zinc ferrite catalyst which is obtained by proportioning a ferric salt, a zinc salt, a cobalt salt, a magnesium salt and a deionized water in a mole ratio, regulating pH value with ammonia water, concentrating, filtering, drying, roasting, cooling, grinding and screening. The method for preparing 1,3-butadiene by utilizing the catalyst comprises the following steps of: with C4 fraction produced by MTO (methanol to olefin) as a raw material, carrying out catalytic oxidative dehydrogenation reaction on a reaction mixture which is formed by the C4 fraction, air and vapour under the action of the cobalt and magnesium modified zinc ferrite catalyst so as to efficiently prepare1,3-butadiene, wherein the main ingredient of the C4 fraction is n-butene. The method disclosed by the invention has the advantage that the C4 fraction is not required to be refined to remove impurities such as oxygenated chemicals, thus the method disclosed by the invention is a simple and efficient method for preparing a high-additional-value product by utilizing C4 resource of the MTO.

The invention discloses a method for recovering lithium from a waste lithium battery to prepare battery grade lithium carbonate. Lithium is extracted from the waste lithium battery as a raw material to prepare the battery grade lithium carbonate. The method mainly comprises the following steps of (1) battery dismantling; (2) acidifying and leaching; (3) iron and aluminum removal; (4) fluorinating lithium deposition; (5) magnesium salt transformation; (6) alkalifying impurity removal; and (7) lithium deposition employing sodium carbonate. The lithium is recovered from the waste lithium battery to prepare the battery grade lithium carbonate, so that the battery grade lithium carbonate has the advantages of being high in lithium recovery rate, small in losses of other metal elements, friendly to environment and high in product purity; the main content of a product exceeds 99.5%; the requirements of battery grade products are met; and the method is simple in process, low in production cost and suitable for industrial production.

An inkjet recording method which suppresses feathering and color bleeding and is excellent in fixability to a recording medium. The inkjet recording method includes the steps of applying an ink-receiving solution prepared by dissolving in an aqueous solvent at least one metal salt having a water solubility of 0.1 mol/l or more, selected from calcium salts, magnesium salts, nickel salts and zinc salts having a valence of 2 or more, to at least the surface to be printed by using an inkjet ink or the entire surface of a recording medium; and printing on the metal salt adhered part by using the inkjet ink comprising at least a pigment, a resin emulsion and an aqueous solvent containing a surfactant. Further, a phosphorus-containing group having at least one P—O or P═O bond is bound to the surface of the pigment.

A method for mass production of high-quality hollow carbon nanocages comprises the following steps: 1) light magnesium carbonate or magnesium carbonate is added into a reaction tube and spread evenly, the tube is put into a tubular furnace, air is pumped out of the tube, inert gas such as N2 and Ar is injected; the reaction temperature is increased to 670 DEG C-900 DEG C, (C) source vapor is introduced, and reaction is carried out for 5 to 240 minutes under the protection of 10-500sccm inert gas atmosphere; the (C) source gas is led to the reaction area of the tubular furnace by the inert gas flow, carbonized on the surfaces of nano particles generated in situ, and covered to form a MgO@C structure; after the reaction, the temperature inside the reaction tube drops to the room temperature under the protection of the inert gas; 2) powder is collected from the reaction tube, dipped in sufficient hydrochloric acid or sulphuric acid for 5 to 720 minutes to remove the kernel of MgO, filtered, washed to neutrality by using deionized water, and dried to obtain the hollow carbon nanocages; and 3) the magnesium salt filtrate is recycled. The nanocages prepared by the method have high purity, and the price for the precursor is low, thereby facilitating recovery and reuse.

Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises minocycline, a magnesium salt, and a sulfite compound in a non-aqueous solvent. In yet another aspect, the topical composition comprises a tetracycline-class drug, a source of magnesium, a monohydric aliphatic alcohol, and a polyol, wherein (i) the ratio between the monohydric aliphatic alcohol and the propylene glycol is in the range of 1:1 to 99:1 by weight and (ii) the tetracycline-class drug is dissolved in the topical composition.